201 related articles for article (PubMed ID: 28184015)
1. Dual PI3K/mTOR Inhibition in Colorectal Cancers with
Foley TM; Payne SN; Pasch CA; Yueh AE; Van De Hey DR; Korkos DP; Clipson L; Maher ME; Matkowskyj KA; Newton MA; Deming DA
Mol Cancer Res; 2017 Feb; 15(3):317-327. PubMed ID: 28184015
[TBL] [Abstract][Full Text] [Related]
2. MTORC1/2 Inhibition as a Therapeutic Strategy for
Fricke SL; Payne SN; Favreau PF; Kratz JD; Pasch CA; Foley TM; Yueh AE; Van De Hey DR; Depke MG; Korkos DP; Sha GC; DeStefanis RA; Clipson L; Burkard ME; Lemmon KK; Parsons BM; Kenny PA; Matkowskyj KA; Newton MA; Skala MC; Deming DA
Mol Cancer Ther; 2019 Feb; 18(2):346-355. PubMed ID: 30425131
[No Abstract] [Full Text] [Related]
3. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA and APC mutations are synergistic in the development of intestinal cancers.
Deming DA; Leystra AA; Nettekoven L; Sievers C; Miller D; Middlebrooks M; Clipson L; Albrecht D; Bacher J; Washington MK; Weichert J; Halberg RB
Oncogene; 2014 Apr; 33(17):2245-54. PubMed ID: 23708654
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.
Payne SN; Maher ME; Tran NH; Van De Hey DR; Foley TM; Yueh AE; Leystra AA; Pasch CA; Jeffrey JJ; Clipson L; Matkowskyj KA; Deming DA
Oncogenesis; 2015 Oct; 4(10):e169. PubMed ID: 26436951
[TBL] [Abstract][Full Text] [Related]
6. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
7. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
8. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Roper J; Richardson MP; Wang WV; Richard LG; Chen W; Coffee EM; Sinnamon MJ; Lee L; Chen PC; Bronson RT; Martin ES; Hung KE
PLoS One; 2011; 6(9):e25132. PubMed ID: 21966435
[TBL] [Abstract][Full Text] [Related]
9. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Dey N; Sun Y; Carlson JH; Wu H; Lin X; Leyland-Jones B; De P
Am J Cancer Res; 2016; 6(4):714-46. PubMed ID: 27186427
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenesis of PIK3CA.
German S; Aslam HM; Saleem S; Raees A; Anum T; Alvi AA; Haseeb A
Hered Cancer Clin Pract; 2013 Jun; 11(1):5. PubMed ID: 23768168
[TBL] [Abstract][Full Text] [Related]
15. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
18. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
[TBL] [Abstract][Full Text] [Related]
19. Sensitivities and Dependencies of
Voutsadakis IA
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295658
[No Abstract] [Full Text] [Related]
20. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
